Quercus Macrocarpa Pollen

Dosage for Quercus Macrocarpa Pollen is highly individualized and must be determined by a specialist. There is no 'standard' dose due to the non-standardized nature of the extract.

Diagnostic Dosing

• Prick/Puncture Test: Usually performed using a 1:10 or 1:20 w/v glycerinated extract. A single drop is applied to the skin, and the skin is pricked through the drop.
• Intradermal Test: If the prick test is negative, a 1:1000 to 1:100 w/v aqueous dilution may be injected into the skin layer (0.02 mL) to check for sensitivity.

Immunotherapy Dosing (Subcutaneous Injection)

• Build-up Phase: Treatment usually begins with a very dilute solution (e.g., 1:100,000 w/v). Injections are given 1–2 times per week. The dose is incrementally increased by 0.05 mL to 0.1 mL at each visit, provided no significant local or systemic reactions occur.
• Maintenance Phase: Once the 'top dose' or 'maintenance dose' is reached (often 0.5 mL of a 1:100 or 1:20 w/v solution), the interval between injections is increased to every 2–4 weeks. Maintenance therapy typically continues for 3 to 5 years.

Quercus Macrocarpa Pollen is generally considered safe for use in children, typically starting at age 5. Dosing protocols for children are identical to adult protocols, though the physician may choose a more conservative build-up schedule depending on the child's sensitivity and history of asthma.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared via traditional renal pathways. However, the patient's overall health and ability to tolerate a systemic reaction must be considered.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment. The metabolic breakdown of the pollen proteins is not dependent on liver function.

Elderly Patients

Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The use of epinephrine (the primary treatment for a severe reaction) may be riskier in this population. Healthcare providers may choose a lower maintenance dose or a slower build-up phase.

Quercus Macrocarpa Pollen must ONLY be administered by a healthcare professional in a clinical setting equipped to handle anaphylaxis.

• Administration: The extract is injected subcutaneously (under the skin), usually in the back of the upper arm.
• Observation: Patients MUST remain in the clinic for at least 30 minutes following an injection. Most life-threatening reactions occur within this window.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). They should not be frozen. Keep vials away from light.

If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on how much time has passed. If a dose is missed during the maintenance phase by more than 1-2 weeks, the physician will likely reduce the dose for the next injection to ensure safety. Never 'double up' on doses to make up for a missed one.

An overdose in the context of allergenic extracts refers to receiving a dose higher than the patient's current tolerance level. This can lead to a severe systemic reaction or anaphylaxis.

• Signs: Hives, swelling of the throat, wheezing, low blood pressure, or rapid heart rate.
• Emergency Measures: Immediate administration of epinephrine (0.3 mg for adults), followed by antihistamines, corticosteroids, and emergency transport to a hospital.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or frequency of visits without medical guidance. Regularity is key to the success of immunotherapy.

Most patients undergoing immunotherapy with Quercus Macrocarpa Pollen will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Local Wheal and Flare: Redness, itching, and swelling at the injection site. This typically appears within minutes and resolves within a few hours.
• Delayed Local Swelling: A larger area of swelling (sometimes the size of a golf ball or larger) that appears 6 to 24 hours after the injection. This can be treated with ice packs and over-the-counter pain relievers.
• Nasal Congestion: Some patients report a temporary increase in hay fever symptoms shortly after the injection.

• Generalized Pruritus: Itching that occurs away from the injection site, such as on the palms, soles, or scalp.
• Urticaria (Hives): The appearance of itchy red welts across various parts of the body.
• Mild Wheezing: A slight tightening of the chest, particularly in patients with a history of asthma.
• Fatigue: Some patients report feeling unusually tired on the day of their injection.

• Angioedema: Deep tissue swelling, often affecting the lips, eyelids, or throat.
• Hypotension: A sudden drop in blood pressure, which may cause dizziness or fainting.
• Laryngeal Edema: Swelling of the larynx (voice box), which can obstruct the airway.
• Persistent Cough: A dry, hacking cough that begins shortly after administration.

> Warning: Stop taking Quercus Macrocarpa Pollen and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis.

• Anaphylaxis: A systemic, life-threatening allergic reaction. It often starts with a 'sense of impending doom,' followed by difficulty breathing, swelling of the tongue, and a rapid, weak pulse.
• Severe Bronchospasm: Intense wheezing and inability to catch one's breath, requiring emergency bronchodilators.
• Syncope (Fainting): Loss of consciousness due to a rapid drop in blood pressure.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.

There are no known long-term 'toxic' side effects associated with Quercus Macrocarpa Pollen when used as directed. The primary long-term effect is the desired modulation of the immune system. However, patients who experience frequent large local reactions may develop minor subcutaneous thickening at the injection sites over several years. There is no evidence that long-term immunotherapy increases the risk of autoimmune diseases or cancer.

While Quercus Macrocarpa Pollen may not have a specific 'Black Box' on every individual manufacturer label, the FDA requires a general class warning for all allergenic extracts regarding the risk of severe anaphylaxis.

Summary of Warning: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients with unstable or severe asthma are at higher risk. Extracts should only be administered by physicians prepared to manage anaphylaxis. Patients must be observed for at least 30 minutes post-injection. Certain medications, like beta-blockers, may increase the risk or make the reaction more difficult to treat.

Report any unusual symptoms, even those that seem minor, to your healthcare provider before your next scheduled injection.

Quercus Macrocarpa Pollen is a potent biological product. Safety depends on accurate dosing and the patient's current health status. It is vital that patients are honest with their providers about how they felt after the previous dose and whether they are currently experiencing any asthma symptoms or infections.

No specific FDA black box warning exists for Quercus Macrocarpa Pollen individually, but it is covered under the general clinical warning for all allergenic extracts. This warning emphasizes that these products are intended for use only by physicians who are experienced in the administration of allergenic extracts and the management of anaphylaxis. The warning also highlights that patients with severe or poorly controlled asthma should not receive immunotherapy due to the high risk of fatal bronchospasm.

• Anaphylaxis Risk: The primary risk is a systemic allergic reaction. This risk is higher during the build-up phase, when switching to a new vial, or if the patient is highly sensitive.
• Asthma Status: If a patient's asthma is flaring up (e.g., peak flow is down, or they are using a rescue inhaler more often), the injection should be postponed. Uncontrolled asthma is the leading risk factor for fatal reactions to immunotherapy.
• Infection: Patients with an active fever or respiratory infection should delay their injection until they have recovered.
• Injection Site: The injection must be subcutaneous. Accidental intravenous injection can cause immediate, severe anaphylaxis.

• Pre-Injection Assessment: The provider should check the patient's current symptoms and the size of the reaction from the last injection.
• Post-Injection Observation: A mandatory 30-minute wait in the clinic is required. Some clinics may require longer for high-risk patients.
• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used before and after the injection to ensure lung function is stable.

Most patients can drive and operate machinery after their 30-minute observation period. However, if a patient feels lightheaded, dizzy, or experiences a systemic reaction, they should not drive and should seek medical assistance.

There is no direct chemical interaction between alcohol and Quercus Macrocarpa Pollen. However, alcohol can cause vasodilation (widening of blood vessels), which might theoretically accelerate the absorption of the allergen or worsen the symptoms of an allergic reaction. It is generally advised to avoid alcohol for several hours after an injection.

Immunotherapy is typically discontinued after 3 to 5 years of successful treatment. If a patient experiences a severe systemic reaction, the physician may decide to discontinue treatment or significantly reduce the dose. There is no 'withdrawal syndrome' associated with stopping Quercus Macrocarpa Pollen, but allergy symptoms may eventually return if the immune system was not fully desensitized.

> Important: Discuss all your medical conditions, especially respiratory or heart problems, with your healthcare provider before starting Quercus Macrocarpa Pollen.

• Beta-Blockers (e.g., Propranolol, Atenolol): These medications are generally contraindicated for patients receiving immunotherapy. If a patient on a beta-blocker has an anaphylactic reaction, the beta-blocker prevents epinephrine from working effectively. This can make a reaction life-threatening and difficult to reverse.
• Uncontrolled Asthma Medications: While not a drug-drug interaction, the use of Quercus Macrocarpa Pollen in a patient whose asthma is not managed by their current regimen is contraindicated due to the high risk of death from bronchospasm.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): These blood pressure medications may increase the risk of more severe systemic reactions or interfere with the body's natural compensatory mechanisms during an allergic reaction.
• MAOIs (Monoamine Oxidase Inhibitors): These can potentiate the effects of epinephrine, which might be used to treat a reaction, leading to dangerous spikes in blood pressure.
• Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs can increase the cardiovascular response to epinephrine, complicating the management of anaphylaxis.

• Antihistamines (e.g., Loratadine, Cetirizine): These can mask the early warning signs of a systemic reaction (like itching or hives). While often used to manage local reactions, their use should be disclosed to the allergist so they can accurately assess the patient's sensitivity.
• Systemic Corticosteroids: Long-term use of steroids may suppress the immune response, potentially making the immunotherapy less effective or masking reactions.

• No specific food interactions exist for Quercus Macrocarpa Pollen. However, patients with 'Oral Allergy Syndrome' (Pollen-Food Allergy Syndrome) may find that their sensitivity to certain fruits (like apples or stone fruits, which can cross-react with tree pollens) increases slightly during the build-up phase of immunotherapy.

• St. John's Wort: May theoretically affect the metabolism of other medications used to treat reactions, though no direct interaction with the pollen extract is known.
• Immunostimulants (e.g., Echinacea): These could theoretically interfere with the goal of desensitization, which is a controlled modulation of the immune system.

• Skin Testing: The most significant interaction is with antihistamines and certain antidepressants, which can suppress the skin's 'wheal and flare' response, leading to a false-negative result in allergy testing. These must be stopped several days before testing.
• Total IgE: Immunotherapy may cause a transient rise in total serum IgE levels before they eventually decline over the course of years.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure, heart rhythm, or depression.

• Severe, Uncontrolled Asthma: Patients with a Forced Expiratory Volume (FEV1) consistently below 70% of predicted value or those with frequent exacerbations should not receive Quercus Macrocarpa Pollen. The risk of a fatal asthma attack triggered by the injection is too high.
• Recent Myocardial Infarction (Heart Attack): Patients who have had a recent heart attack or have unstable angina cannot tolerate the physiological stress of a systemic reaction or the administration of epinephrine.
• History of Severe Anaphylaxis to Oak Extract: If a patient has previously had a near-fatal reaction to this specific extract, the risks of continuing therapy usually outweigh the benefits.
• Beta-Blocker Therapy: As mentioned, the inability to treat anaphylaxis effectively due to beta-blockade is an absolute contraindication in most clinical guidelines.

• Pregnancy (Initiation): Immunotherapy should not be started during pregnancy because of the risk of anaphylaxis, which can cause fetal hypoxia (lack of oxygen). However, if a woman is already on a stable maintenance dose and becomes pregnant, she may often continue treatment.
• Autoimmune Diseases: Patients with active, severe autoimmune disorders may have unpredictable immune responses to immunotherapy.
• Malignancy: Patients undergoing active chemotherapy or with certain cancers may not be suitable candidates due to their compromised or altered immune status.
• Children under Age 5: Due to the difficulty of children this age communicating early symptoms of a systemic reaction, immunotherapy is often delayed.

Patients allergic to Quercus Macrocarpa (Bur Oak) are highly likely to be cross-sensitive to other members of the Quercus genus (e.g., White Oak, Red Oak). There is also potential cross-reactivity with other trees in the Fagaceae family, such as Beech and Chestnut trees. This means that a reaction to one may indicate a potential reaction to others.

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and cardiovascular health, before prescribing Quercus Macrocarpa Pollen.

Quercus Macrocarpa Pollen is classified by the FDA in Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm. The primary concern during pregnancy is not the extract itself, but the risk of maternal anaphylaxis. Anaphylaxis can lead to maternal hypotension and uterine contraction, resulting in fetal hypoxia or miscarriage.

Clinical Practice: Most allergists will not start a new course of immunotherapy in a pregnant patient. However, if a patient is already at a maintenance dose and is tolerating it well, the treatment is often continued at the same or a slightly reduced dose throughout pregnancy.

There is no evidence that Quercus Macrocarpa Pollen proteins are excreted into breast milk in any significant amount, or that they would be harmful to a nursing infant. Most experts consider it safe to continue immunotherapy while breastfeeding.

Immunotherapy is generally approved for children aged 5 and older. It is particularly beneficial in children as it may prevent the development of new sensitivities and reduce the risk of progressing from allergic rhinitis to asthma. Dosing must be cautious, and the child must be able to cooperate with the 30-minute observation period.

In patients over age 65, the decision to use Quercus Macrocarpa Pollen must be weighed against the increased likelihood of comorbid conditions. Elderly patients are more likely to have cardiovascular disease, which makes them more vulnerable to the effects of a systemic reaction and the epinephrine used to treat it. A thorough cardiac evaluation is often recommended before starting therapy in this age group.

There are no specific guidelines for renal impairment. Because the product is a protein extract and not a drug cleared by the kidneys, standard dosing is typically used. However, the clinician should monitor the patient's overall fluid status and blood pressure stability.

No adjustments are needed for patients with liver disease. The liver does not play a primary role in the clearance of injected allergenic proteins.

> Important: Special populations require individualized medical assessment. Always inform your specialist if you are pregnant, planning to become pregnant, or have any chronic health conditions.

Quercus Macrocarpa Pollen extract acts as an immunomodulator. In an allergic individual, the immune system is 'sensitized,' meaning it has produced IgE antibodies that recognize oak pollen proteins. When the extract is injected, it is processed by antigen-presenting cells (APCs) such as dendritic cells. These APCs present the pollen peptides to T-lymphocytes.

Repeated exposure through immunotherapy leads to the following molecular changes:

1. 1T-cell Anergy: Reduction in the responsiveness of Th2 cells.
2. 2Regulatory T-cell (Treg) Induction: Tregs produce IL-10, which suppresses IgE production and inhibits mast cell activation.
3. 3B-cell Switching: B-cells stop producing IgE and start producing IgG4. IgG4 acts as a 'blocking antibody,' binding to the pollen proteins before they can reach the IgE on mast cells.
4. 4Reduced Effector Cell Recruitment: There is a decrease in the number of eosinophils and basophils that migrate to the site of allergen exposure (e.g., the nasal mucosa).

The effects of Quercus Macrocarpa Pollen are not immediate. While skin testing shows a reaction within 15–20 minutes, the therapeutic effect of desensitization takes months to develop. The duration of effect can be long-lasting; many patients maintain their tolerance for years after completing a 3-to-5-year course of treatment.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous injection results in 100% absorption into local tissue) |

| Protein Binding | N/A (Allergen proteins interact with antibodies and receptors) |

| Half-life | Varies by protein (Typically hours to days for immune processing) |

| Tmax | 30–60 minutes for systemic absorption of major allergens |

| Metabolism | Proteolysis by tissue and cellular enzymes |

| Excretion | Cellular turnover/metabolic degradation |

Quercus Macrocarpa Pollen extract is a complex mixture of proteins, glycoproteins, and polysaccharides. The primary allergenic proteins in oak are often referred to as 'Que m' allergens (e.g., Que m 1).

• Molecular Weight: Ranges from 10 kDa to over 70 kDa for various protein fractions.
• Solubility: Soluble in aqueous buffers and physiological saline.
• Structure: Complex tertiary protein structures that must remain intact for biological activity.

It is classified as an Allergenic Extract and further categorized as a Non-Standardized Pollen Allergenic Extract [EPC]. It is related to other tree pollen extracts like White Oak, Birch, and Hickory extracts.